Evaluating only ClinicalPAD’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Competition.
Key Events Timeline
FOUNDING
Founded in Boston to provide tablet-based ePRO data capture replacing paper diaries in Phase II-III clinical trials.
FUNDING
Raised $7M Series A; signed contracts with 6 top-20 pharma companies; ARR grew to $8M.
PIVOT
Medidata and Oracle began bundling ePRO as free add-on to CTMS contracts; ClinicalPAD began losing renewals.
SHUTDOWN
ARR fell from $8M to $3M; failed M&A process; team of 35 laid off; platform decommissioned.
Full Analysis
Free · no account needed
Documented cause
ClinicalPAD developed a tablet-based electronic patient-reported outcomes (ePRO) platform for clinical trials and outpatient monitoring, raising $11M. The company faced fierce competition from Medidata, Oracle Health Sciences, and ERT — larger players offering bundled solutions at discounted rates. By 2021, ClinicalPAD had lost four of its top six pharma clients to competitors, its ARR declined from $8M to $3M, and it quietly ceased operations after a failed acquisition process.
Lesson
“Point solutions in clinical trials face bundling death — you need defensible differentiation or risk being a feature.”